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Supplementary Figure 1 
 
 
 
Supplementary Figure 1. Percentages of immune cells are distributed normally in the 
spleens of naïve F12
−/−
 mice compared with controls. Total splenocytes of naïve WT and 
F12
−/−
 animals were analyzed for surface or intranuclear expression of the indicated markers 
by flow cytometry. Data are representative of three independent experiments with three mice 
per genotype. 
2 
 
Supplementary Figure 2 
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Supplementary Figure 2. Brain-infiltrating leukocytes (BIL) from WT and F12
−/−
 mice 
were analyzed at dmax of EAE. BIL isolated from WT and F12
−/−
 mice were stained for 
indicated surface and intranuclear markers before flow cytometric examination. (a) Cell 
surface staining for CD45 allowed assessing the amount of peripheral infiltration into the 
CNS at dmax (day 16) of EAE. Thus, the number of CD45
high
 cells calculated relative to 1.0 × 
10
4
 reference beads is shown. (b) BIL were further analyzed for the numbers of 
CD45
high
CD11b
−
 (1, identifying peripheral lymphocytes), CD45
high
CD11b
+
 (2, identifying 
peripheral macrophages and dendritic cells), and CD45
low
CD11b
+
 (3, identifying microglia) 
cells relative to 1.0 × 10
4
 reference beads. (c) Representative dot plots showing the 
percentages of central nervous system-infiltrating CD4
+
, CD8
+
, CD11c
+
, CD11b
+
, and 
CD4
+
Foxp3
+
 cells. In a and b, data are given as means ± s.e.m. of two independent 
experiments with four mice per genotype (non-parametric Mann-Whitney U-test). 
Representative dot plots for indicated markers are displayed. In c, data are representative of 
three independent experiments with three or four mice per genotype. 
*
P < 0.05; FSC, forward 
scatter; ns, not significant; SSC, side scatter. 
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Supplementary Figure 3 
 
 
 
Supplementary Figure 3. Reduced percentages of IL-17A-producing CD4
+
CD40L
+
 T 
cells at day 10 of EAE. CD4
+
 T cells (3 × 10
6
) isolated from the LN of WT and F12
−/−
 mice 
at day 10 of EAE were restimulated with different concentrations of MOG35–55. After 2 days, 
the percentages of IL-17A- and IFN-γ-producing CD4+CD40L+ T cells were determined by 
flow cytometry. Data are representative of three independent experiments with three or four 
mice per genotype (non-parametric Mann-Whitney U-test). 
*
P < 0.05, 
***
P < 0.001. 
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Supplementary Figure 4 
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Supplementary Figure 4. Protection from EAE in F12
−/−
 mice is independent of the 
kallikrein–kinin, the complement, or the coagulation system. (a) Bradykinin release in 
serum and CSF of naïve and MOG35–55-immunized WT and F12
−/−
 animals at dmax (day 16) of 
EAE. (b) B1r and B2r gene expression in the spinal cords of WT and F12
−/−
 mice at dmax as 
determined by rRT-PCR using 18sRNA for normalization. Data are given as fold change in 
normalized expression in MOG35–55-immunized animals relative to vehicle-injected controls. 
(c) In vitro migration of LN cells from WT and F12
−/−
 mice across inflamed MBMEC of WT 
and B1r
−/−
 mice. (d) Fibrin/fibrinogen deposition, as quantified by optical density 
measurements, in the spinal cords of WT and F12
−/−
 mice at dmax of EAE. (e) Active EAE was 
induced in WT and F11
−/−
 mice by immunization with MOG35–55. Clinical scores (mean ± 
s.e.m.) over time of two independent EAE experiments are shown. (f) Histological analysis of 
spinal cord sections from the lumbar region of WT and F11
−/−
 animals at dmax. Sections were 
stained with hematoxylin & eosin (HE) to evaluate inflammatory foci (left panel) and 
immunostained for Luxol fast blue (LFB) to assess demyelination (right panel). Arrows 
indicate inflammation or demyelinated areas, respectively. Scale bars, 100µm. (g) 
Proliferation and cytokine production by CD4
+
 T cells purified from LN 10 days after 
immunization and restimulated with 10 µg ml
-1
 MOG35–55 and irradiated (35 Gy) antigen-
presenting cells in vitro for 48 hours. (h) Activation of the complement component C5 to C5a 
in sera of naïve and MOG35–55-immunized WT and F12
−/−
 mice at dmax. For a-d, data are 
mean ± s.e.m. of three independent experiments, each performed in duplicate or triplicate. For 
f-h, data are presented as mean ± s.e.m. of two independent experiments. For a-h, non-
parametric Mann-Whitney U-test or student t-test.
 *
P < 0.05, 
***
P < 0.001; AU, arbitrary units; 
ns, not significant. 
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Supplementary Figure 5 
 
 
 
Supplementary Figure 5. CD4
+
 T-cell polarization is unaltered in the presence of FXII. 
(a) Naïve CD4
+
CD62L
+
 T cells from WT LN were polyclonal activated with 5 µg ml
-1
 plate-
bound anti-CD3 and 1 µg ml
-1
 soluble anti-CD28 (TH0) in the presence or absence of FXII. 
After 48 hours of polyclonal stimulation, proliferation and production of the indicated 
cytokines were determined. (b) Naïve CD4
+
CD62L
+
 T cells were activated with anti-CD3 and 
anti-CD28 in the presence of different recombinant cytokine/neutralizing antibody mixtures 
specific for TH1, TH17, or inducible Treg (iTreg) (see Methods). In a and b, data are given as 
means ± s.e.m. of three independent experiments, each performed in triplicate (non-
parametric Mann-Whitney U-test; ns, not significant).  
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Supplementary Figure 6 
 
 
 
Supplementary Figure 6. DC of F12
−/−
 animals have unaltered surface markers. Splenic 
pDC (upper panel) and cDC (lower panel) of WT and F12
−/−
 animals were analyzed for 
surface expression of the indicated markers by flow cytometry. Data are representative of 
three independent experiments with three mice per genotype.  
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Supplementary Figure 7 
 
 
10 
 
Supplementary Figure 7. FXII has no influence on surface markers of mouse cDC. 
Splenic cDC of WT animals were incubated with medium only (Ctrl) or stimulated with LPS 
(1 µg ml
-1
) in the absence or presence of FXII and analyzed for surface expression of CD40 
(a), CD87 (b), CD80 (c), CD86 (d), and MHC-II (e) by flow cytometry. In a-e, 
quantifications of indicated markers are given as mean ± s.e.m. of three independent 
experiments with three mice per genotype. Representative FACS plots for indicated markers 
are also shown. 
*
P<0.05, 
***
P<0.001 by one way ANOVA and Tukey’s multiple comparisons 
test. MFI, mean fluorescence intensity; ns, not significant. 
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Supplementary Figure 8 
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Supplementary Figure 8. FXII has no influence on MBMEC, astrocytes or microglia. (a) 
rRT-PCR analyses for Cd87 gene expression in primary cell cultures of MBMEC, microglial 
and astroglial cells are shown. (b) The transendothelial resistance (TER) of naïve MBMEC or 
MBMEC inflamed (infl.) with IFN-γ and TNF-α (each 500 IU ml-1) in the absence or 
presence of 60 nM factor XII (FXII) was monitored after 24 hours. (c) Twenty-four hours 
post inflammation, MBMEC supernatants were collected and the concentrations of indicated 
proinflammatory chemokines were assessed by flow cytometry. (d) To assess MBMEC 
permeability, 24 hours post inflammation with or without FXII, naïve splenocytes from wild-
type mice were allowed to migrate. The number of migrated cells relative to 1.0 × 10
4
 
reference beads was determined for each group by flow cytometry. (e, f) Histologic analysis 
of microglia and astrocyte cultures prior treated with 1 µg ml
-1
 LPS, or 1 µg ml
-1
 LPS and 60 
nM FXII for 24 hours. (e) Microglia and (f) astrocyte cultures were stained with CD11b 
(green) or glial fibrillary acidic protein (GFAP; green), respectively. Both cell cultures were 
analyzed for the expressions of MHC-I (left) and MHC-II (right). Scale bars, 20µm. (g, h) 
Production of the indicated cytokines was assessed in supernatants of (g) microglia and (h) 
astrocyte cultures after treatment with 1 µg ml
-1
 LPS, or 1 µg ml
-1
 LPS and 60 nM FXII for 24 
hours. (i, j) Histologic analysis of spinal cord sections from the lumbar region of MOG35–55-
immunized WT animals at dmax (day 16). Sections were stained for (i) ionized calcium-
binding adapter molecule 1 (Iba1, red) and nucleus (DAPI, blue), or (j) GFAP (red) and 
nucleus (DAPI, blue). Scale bars, 50µm. Data are presented as mean ± s.e.m. of two 
independent experiments.
 
For a-j, Kruskal-Wallis test with Dunn post hoc analysis in the case 
of multiple comparisons or non-parametric Mann-Whitney U-test.
 *
P < 0.05, CXCL, 
Chemokine (C-X-C motif) ligand; CCL, chemokine (C-C motif) ligand; MIP, macrophage 
inflammatory protein; nd, not detected; ns, not significant; uninfl., uninflamed.  
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Supplementary Figure 9 
 
 
 
Supplementary Figure 9. rHA-Infestin-4 linked to human albumin cannot be found in 
the CNS of EAE mice. Histologic analysis of human liver (left panel) and spinal cord 
sections from the lumbar region (right panel) of rHA-Infestin-4-treated EAE mice at dmax (day 
16). Sections were stained for human albumin (red) and nucleus (DAPI, blue). Scale bar, 
50µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
Supplementary Figure 10 
 
 
 
Supplementary Figure 10. Full scan of western blot experiment are shown. For detailed 
information see Supplementary Figure 4d.  
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Supplementary Table 1. Detailed information on EAE experiments with F12
−/− 
mice 
induced with MOG35–55  
 
Exp. 
no. 
Mice n Incidence (%) 
Drop out 
(%) 
Day of onset 
(mean ± s.e.m.) 
Maximum score 
(mean ± s.e.m.) 
1 WT 9 100 11.1 12.1 ± 0.6 5.4 ± 0.3 
1 F12
−/−
 7 100 0 14.1 ± 0.7 3.1 ± 0.6 
 P = 0.347 P = 0.030 P = 0.011 
2 WT 6 100 16.7 11.7 ± 0.3 5.7 ± 0.2 
2 F12
−/−
 10 90 0 13.8 ± 0.6 3.5 ± 0.7 
 P = 0.363 P = 0.033 P = 0.018 
3 WT 8 100 12.5 11.4 ± 0.4 6.0 ± 0.4 
3 F12
−/−
 10 90 0 15.2 ± 0.8 3.6 ± 0.5 
 P = 0.350 P = 0.001 P = 0.004 
Exp., Experiment; s.e.m., standard error of the mean. 
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Supplementary Table 2. Immune cell distribution in spleens, LN and brain-infiltrating 
leukocytes (BIL) of naïve (−) and MOG35–55-immunized (+) in WT and F12
−/−
 animals  
 Spleen LN BIL 
Mouse 
strain 
WT F12
−/−
 WT F12
−/−
 WT F12
−/−
 
MOG35–55 − + − + − + − + − + − + 
Cell phenotype 
% of total viable cells 
CD4
+
 17.7 12.6 17.4 11.1
†
 21.1 15.9 21.0 15.3 nd 6.6 nd 0.7
§
 
CD8
+
 12.6 9.5
†
 12.7 8.2 16.4 14.4 18.7 14.0 nd 0.9 nd 0.3
§
 
γδ+ 2.2 1.4* 1.8 1.5 0.8 0.6 0.6 0.9 nd 0.3 nd 0.4 
B220
+
 45.9 38.3
†
 48.6 38.6
†
 18.3 33.4
†
 18.2 31.2
†
 nd 5.5 nd 6.6 
CD11b
+
 5.6 28.7
*
 5.6 27.8
*
 nd nd nd nd nd 14.0 nd 1.7
§
 
CD11c
+
 3.9 2.6 2.6
§
 2.4 5.7 5.6 5.2 5.9 nd 5.0 nd 0.9
§
 
% of gated CD4
+
 cells 
CD25
+
 8.6 7.3 9.6 8.0 11.0 12.8 12.2 13.7 nd 21.5 nd 15.2
§
 
Foxp3
+
 7.1 6.9 7.8 7.9 9.6 11.8
†
 11.8
§
 12.8 nd 12.4 nd 9.2 
Nd, not detected. *, P < 0.01 (EAE vs. respective control), 
†
, P < 0.05 (EAE vs. respective 
control), 
§
, P < 0.05 (F12
−/−
 vs. WT) 
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Supplementary Table 3. Detailed information on EAE experiments under rHA-Infestin-
4 treatment in C57BL/6 mice immunized with MOG35–55 
Exp. 
no. 
Treatment n 
Incidence 
(%) 
Drop out 
(%) 
Day of onset 
(mean ± s.e.m.) 
Maximum score 
(mean ± s.e.m.) 
1 Vehicle 8 100 12.5 8.6 ± 0.4 6.5 ± 0.1 
1 rHA-
Infestin-4 
8 100 0 10.3 ± 0.5 5.1 ± 0.2 
 P = 0.351 P = 0.031 P = 0.033 
2 Vehicle 10 100 10.0 11.4 ± 0.4 6.3 ± 0.3 
2 rHA-
Infestin-4 
8 90 0 12.8 ± 0.4 4.0 ± 0.6 
 P = 0.343 P = 0.036 P = 0.012 
Exp., Experiment; s.e.m., standard error of the mean. 
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Supplementary Table 4. Detailed information about EAE under rHA-Infestin-4 
treatment in SJL/JRj mice immunized with proteolipid protein peptide 139–151  
Mice Treatment n 
Incidence 
(%) 
Drop out 
(%) 
Day of onset 
(mean ± 
s.e.m.) 
First attack 
score (mean 
± s.e.m.) 
Second 
relapse score 
(mean ± 
s.e.m.) 
SJL Vehicle 9 100 0 8.8 ± 0.2 5.1 ± 0.7 4.0 ± 0.2 
SJL rHA-
Infestin-4 
9 100 0 8.6 ± 0.2 5.1 ± 0.6 2.1 ± 0.4 
 P = 0.619 P = 0.879 P = 0.002 
S.e.m., standard error of the mean. 
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Supplementary Table 5. Demographic information on patients and HD included in the 
study  
 CIS RRMS PPMS SPMS HD 
Age (range), 
years 
33.5 (25−51) 37.1 (22−60) 54.0 (44−73) 52.7 (34−72) 45.3 (25−63) 
Male/female  6/13 35/103 6/7 32/58 39/91 
EDSS 1.5 (0−3.0) 2.5 (0−6.5) 4.5 (2.5−7.5) 5.5 (2.5–8.0) − 
No therapy 16 49 5 17 − 
Azathioprine − − − 23 − 
Fingolimod − 25 − − − 
Glatiramer 
acetate 
1 9 − − − 
Interferon 2 27 − 8 − 
Mitoxantrone − 3 3 12 − 
Natalizumab − 25 − − − 
Steroids − − 5 30 − 
Unless otherwise stated, values are the number of individuals. EDSS, Expanded Disability 
Status Scale. 
 
